| pubmed-article:15616062 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15616062 | lifeskim:mentions | umls-concept:C0237401 | lld:lifeskim |
| pubmed-article:15616062 | lifeskim:mentions | umls-concept:C0086045 | lld:lifeskim |
| pubmed-article:15616062 | lifeskim:mentions | umls-concept:C0041657 | lld:lifeskim |
| pubmed-article:15616062 | lifeskim:mentions | umls-concept:C0033487 | lld:lifeskim |
| pubmed-article:15616062 | lifeskim:mentions | umls-concept:C2348205 | lld:lifeskim |
| pubmed-article:15616062 | lifeskim:mentions | umls-concept:C1720052 | lld:lifeskim |
| pubmed-article:15616062 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15616062 | pubmed:dateCreated | 2004-12-23 | lld:pubmed |
| pubmed-article:15616062 | pubmed:abstractText | Reported effect-site concentrations of propofol at loss of consciousness and recovery of consciousness vary widely. Thus, no single concentration based on a population average will prove optimal for individual patients. We therefore tested the hypothesis that individual propofol effect-site concentrations at loss and return of consciousness are similar. Propofol effect-site concentrations at loss and recovery of consciousness were estimated with a target-control infusion system in 20 adults. Propofol effect-site concentrations were gradually increased until the volunteers lost consciousness (no response to verbal stimuli); unconsciousness was maintained for 15 min, and the volunteers were then awakened. This protocol was repeated three times in each volunteer. Our major outcomes were the concentration producing unconsciousness and the relationship between the estimated effect-site concentrations at loss and recovery of consciousness. The target effect-site propofol concentration was 2.0 +/- 0.9 at loss of consciousness and 1.8 +/- 0.7 at return of consciousness (P <0.001). The average difference between individual effect-site concentrations at return and loss of consciousness was only 0.17 +/- 0.32 microg/mL (95% confidence interval for the difference 0.09-0.25 microg/mL). Our results thus suggest that individual titration to loss of consciousness is an alternative to dosing propofol on the basis of average population requirements. | lld:pubmed |
| pubmed-article:15616062 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15616062 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15616062 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15616062 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15616062 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:15616062 | pubmed:issn | 0003-2999 | lld:pubmed |
| pubmed-article:15616062 | pubmed:author | pubmed-author:MatsukawaTaka... | lld:pubmed |
| pubmed-article:15616062 | pubmed:author | pubmed-author:SesslerDaniel... | lld:pubmed |
| pubmed-article:15616062 | pubmed:author | pubmed-author:NagataOsamuO | lld:pubmed |
| pubmed-article:15616062 | pubmed:author | pubmed-author:NishiharaNobo... | lld:pubmed |
| pubmed-article:15616062 | pubmed:author | pubmed-author:OzakiMakotoM | lld:pubmed |
| pubmed-article:15616062 | pubmed:author | pubmed-author:IwakiriHiroko... | lld:pubmed |
| pubmed-article:15616062 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15616062 | pubmed:volume | 100 | lld:pubmed |
| pubmed-article:15616062 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15616062 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15616062 | pubmed:pagination | 107-10 | lld:pubmed |
| pubmed-article:15616062 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:meshHeading | pubmed-meshheading:15616062... | lld:pubmed |
| pubmed-article:15616062 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15616062 | pubmed:articleTitle | Individual effect-site concentrations of propofol are similar at loss of consciousness and at awakening. | lld:pubmed |
| pubmed-article:15616062 | pubmed:affiliation | Department of Anesthesiology, Tokyo Women's Medical University, Tokyo 162-8666, Japan. | lld:pubmed |
| pubmed-article:15616062 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15616062 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15616062 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
